Urticaria – Current Treatment – Detailed, expanded analysis: Treatment Algorithms: Claims Data Analysis – Chronic spontaneous urticaria (US) 2023
The drug market for chronic spontaneous urticaria (CSU; previously known as chronic idiopathic urticaria) is dominated by oral medications, including those approved (e.g., first- and second-generation antihistamines) or used off-label (e.g., DMARDs, immunosuppressants, tricyclic antidepressants) for this disorder. However, several drug classes have serious side effects, and many patients still struggle to control their lesions. Novartis / Roche’s Xolair was the first FDA-approved biologic for CSU treatment, and other biologics are used off-label. Guidelines for CSU were recently updated to remove montelukast and prioritize prescription therapies, but some physicians have been slow to adapt.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed CSU patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed CSU patients?
- How has Xolair been integrated into the treatment algorithm, and what is its source of business?
- What percentage of CSU patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of CSU patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Solution enhancement
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.
Geography: United States
Real world data: Longitudinal patient-level claims data analysis
Key drugs covered: Xolair, Dupixent, montelukast, Xyzal, Vistaril, Zyrtec, Periactin, Elavil, Claritin, Allegra, Benadryl, Atarax, nifedipine, Silenor, Humira, methotrexate, Enbrel, cyclosporine
Key analysis provided: Brand / therapy usage across longitudinal patient sample; newly diagnosed patient analysis; treatment initiation and progression; line of therapy analysis; combination therapy analysis; source of business for recently treated patients; persistency and compliance analysis; product-level patient flowcharts
Table of contents
Shubhendu Ghosh, Ph.D., Senior Healthcare Research & Data Analyst, Immune and Inflammation. Dr. Ghosh’s focus is the asthma and urticaria therapy markets. Previously, he was an associate editor at Nature Structural & Molecular Biology and a copy editor at Nature Medicine. He was also a scientific and developmental editor at Nature Research Editing Service. He holds a Ph.D. in biomedical sciences from the University of Massachusetts Medical School, a B.Sc. in microbiology from Delhi University, and an M.Sc. in biotechnology from Madurai Kamaraj University.